AI Science Tracker

Bayesian language-model design improved measured scFv binding

Massachusetts Institute of Technology Lincoln Laboratory; A-Alpha Bio, Inc. · 7 Oct 2022 · biology

Discovery

Bayesian language-model design improved measured scFv binding

An end-to-end Bayesian language-model workflow designed diverse single-chain antibody fragment libraries that were measured for binding. In the 2023 journal version, the best generated scFv bound 28.7-fold better than the best directed-evolution comparator, and 99% of designs in the most successful library improved on the initial candidate. The 2022 bioRxiv v1 abstract already reported this result chain, giving 28.8-fold for the best generated scFv; the small difference is version-specific. These are in-vitro binding results, not clinical efficacy.

Technology: Bayesian optimization with a language-model-based antibody sequence representation

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: Designed scFvs were empirically measured. The publisher abstract reports the best generated scFv had 28.7-fold greater binding than the best directed-evolution scFv and 99% of the designed scFvs in the most successful library improved on the initial candidate.
  • Still unknown: The journal version reports the best generated scFv at 28.7-fold better binding while the v1 abstract reports 28.8-fold; this minor version discrepancy is retained. The measured binding result does not establish clinical efficacy.
  • AI role: A Bayesian, language-model-based workflow designed candidate scFv libraries, whose binding was experimentally measured.

Evidence sources: https://api.biorxiv.org/details/biorxiv/10.1101/2022.10.07.502662 · https://www.nature.com/articles/s41467-023-39022-2.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Official bioRxiv API v1 date/abstract and primary Nature journal PDF for full result and affiliations..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.